CLINICAL PERSPECTIVES +++++ +++++ +++++ +++

CLINICAL PERSPECTIVES MajesTEC-9 Clinical Trial of Teclistamab in Patients With Multiple Myeloma https://checkrare.com/majestec-9-clinical-trial-of-teclistamab-in-patients-with-multiple-myeloma/ Roberto Mina, MD, Associate Professor at Winship Cancer Institute of Emory University, discusses the Majestec-9 clinical trial of Tecvayli (teclistamab) in patients with multiple myeloma (MM). Long-Term Outcomes From the PIONEER Study in Patients With Indolent Systemic Mastocytosis https://checkrare.com/long-term-outcomes-from-the-pioneer-study-in-patients-with-indolent-systemic-mastocytosis/ Tsewang Tashi, MD, Hematologist at the Huntsman Cancer Institute at the University of Utah, discusses long-term data from the PIONEER clinical trial examining the use of avapritinib in patients with indolent systemic mastocytosis (ISM). Using Artificial Intelligence to Analyze Castleman Disease Histopathology https://checkrare.com/using-artificial-intelligence-to-analyze-castleman-disease-histopathology/ Robert S. Ohgami, MD, PhD, Professor of Pathology, University of Utah, and Founding Vice President and Chief Medical Director, ARUP Institute for Research and Innovation, discusses the utilization of artificial intelligence (AI) to analyze Castleman disease (CD) histopathology. Elritercept’s Effect on Transfusion Independence in Patients With Myelodysplastic Syndromes https://checkrare.com/elritercepts-effect-on-transfusion-independence-in-patients-with-myelodysplastic-syndromes/ Lynette Chee, PhD, Hematologist at The Royal Melbourne Hospital/ Peter MacCallum Cancer Centre, discusses elritercept’s effect on transfusion independence (TI) in patients with myelodysplastic syndromes (MDS). 52-Week Results From the VERIFY Clinical Trial of Rusfertide in Patients With Polycythemia Vera https://checkrare.com/52-week-results-from-the-verify-clinical-trial-of-rusfertide-in-patients-with-polycythemia-vera/ Andrew T. Kuykendall, MD, VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center, discusses 52-week results from the VERIFY clinical trial testing rusfertide in patients with polycythemia vera (PV). Results from the XTEND-ed Clinical Trial Evaluating Efanesoctocog Alfa for the Treatment of Patients With Hemophilia A https://checkrare.com/results-from-the-xtend-ed-clinical-trial-evaluating-efanesoctocog-alfa-for-the-treatment-of-patients-with-hemophilia-a/ Lynn Malec, MD, Versiti Blood Research Institute and Medical College of Wisconsin, discusses results from the XTEND-ed clinical trial evaluating efanesoctocog alfa for the treatment of patients with hemophilia A. Bleximenib Combination Therapy for Patients With Acute Myeloid Leukemia https://checkrare.com/bleximenib-combination-therapy-for-patients-with-acute-myeloid-leukemia/ Hartmut Döhner, MD, Professor of Medicine and Medical Director of the Department of Hematology and Oncology, Ulm University, Germany, discusses bleximenib combination therapy for treatment of patients with acute myeloid leukemia (AML). Rare Diseases in Ireland – New Efforts to Improve Access to Care https://checkrare.com/rare-diseases-in-ireland-new-efforts-to-improve-access-to-care/ Each country takes a different approach to rare diseases, from the way it defines the term to the health policies it implements to its approach to research. SWITCH Clinical Trial Design for Patients With Hemophilia A https://checkrare.com/switch-clinical-trial-design-for-patients-with-hemophilia-a/ Guy Young, MD, Children’s Hospital Los Angeles, discusses the SWITCH clinical trial design for patients with hemophilia A. Phase 2 Results of Dusquetide in the Treatment of Oral Ulcers Caused by Behçet’s Disease https://checkrare.com/phase-2-results-of-dusquetide-in-the-treatment-of-oral-ulcers-caused-by-behcets-disease/ Recently, results from a phase 2a study evaluating SGX945 (dusquetide) for the treatment of Behçet’s disease were published in Rheumatology (Oxford). Real World Safety Data of Enjaymo (Sutimlimab) in Patients With Cold Agglutinin Disease https://checkrare.com/real-world-safety-data-of-enjaymo-sutimlimab-in-patients-with-cold-agglutinin-disease/ Catherine M. Broome, MD, Professor of Medicine and Director of Cellular Apheresis, Lombardi Cancer Center, MedStar Georgetown University, discusses real world safety data of Enjaymo (sutimlimab) in patients with cold agglutinin disease (CAD). Long-term Efficacy of Rilzabrutinib in Patients With Immune Thrombocytopenia https://checkrare.com/long-term-efficacy-of-rilzabrutinib-in-patients-with-immune-thrombocytopenia/ David Kuter, MD, DPhil, Professor of Medicine at Harvard Medical School, Massachusetts General Hospital, discusses treatment with rilzabrutinib in patients with immune thrombocytopenia (ITP). Recent Data on Ravulizumab in Rare Hematologic Conditions https://checkrare.com/recent-data-on-raulizumab-in-rare-hematologic-disorders/ Anita Hill, MD, PhD, Global Medical Head for Hematology & Nephrology and Transplant at Alexion, AstraZeneca Rare Disease, discusses recent data on ravulizumab in rare hematologic conditions. Efficacy of Pozelimab + Cemdisiran To Treat Paroxysmal Nocturnal Hemoglobinuria https://checkrare.com/efficacy-of-pozelimab-cemdisiran-to-treat-paroxysmal-nocturnal-hemoglobinuria/ Jun Ho Jang, MD, PhD, Professor, Division of Hematology-Oncology at Samsung Medical Center, discusses results from an open-label extension study testing pozelimab plus cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria (PNH), who previously received the combination therapy or received ravulizumab. Treatment With Elritercept for Patients With Myelofibrosis https://checkrare.com/treatment-with-elritercept-for-patients-with-myelofibrosis/ Ciro Rinaldi, MD, Consultant Hematologist and Professor of Hematology at United Lincolnshire Hospital, discusses treatment with elritercept for patients with myelofibrosis (MF). Updated Phase 2 Results of Telquetamab + Teclistamab in Multiple Myeloma https://checkrare.com/updated-phase-2-results-of-telquetamab-teclistamab-in-multiple-myeloma/ Saad Usmani, MD, Myeloma Specialist and Cellular Therapist at Memorial Sloan Kettering Cancer Center, discusses updated results from the phase 2 RedirecTT-1 study of telquetamab + teclistamab in patients with multiple myeloma (MM). Results from the CARTITUDE-4 Clinical Trial in Multiple Myeloma https://checkrare.com/results-from-the-cartitude-4-clinical-trial-in-multiple-myeloma/ Binod Dhakal, MD, Associate Professor of Medicine at Medical College of Wisconsin, discusses results from the CARTITUDE-4 clinical trial in patients with multiple myeloma (MM). Results of Part 1a of the OLYMPIA-3 Study of Odronextamab+Chemotherapy in Diffuse Large B Cell Lymphoma https://checkrare.com/results-of-part-1a-of-the-olympia-3-study-of-odronextamabchemotherapy-in-diffuse-large-b-cell-lymphoma/ Jean-Marie Michot, MD, Institut Gustave Roussy, France, discusses results from Part 1A (dose escalation) of the OLYMPIA-3 study of odronextamab plus chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL).